@Denial
I don't think that necessarily means they'd bundle MPS and OA together in those regions, of course they may, but I don't think these recent results make it more likely. The target population size hasn't changed. The study proved safety with and pointed towards efficacy in a tiny sample size. You speak with so much certainty as if the company has told us is what they will do - I don't think this now confirms that they'd make it part of a regional licensing package MPS + OA.
Ann: PAR Appoints Business Development Consultant, page-112
-
- There are more pages in this discussion • 216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |